BioCentury | Mar 31, 2017
Targets & Mechanisms

Cells on the rise

...studies identified DCUND1 inhibitors that could help treat squamous cell carcinoma of the lung. Herbert Wertheim...
BioCentury | Aug 1, 2013
Tools & Techniques

The liver's new bud

...587-590 (1975) 3. Booth, C. et al. World J. Gastroenterol. 18 , 6926-6934 (2012) 4. Wertheim...
BioCentury | Mar 10, 2011
Targets & Mechanisms

De-amping the HER2 environment

...Boston, Mass. e-mail: jbaselga@partners.org 3. Slamon, D.J. et al. Science 235 , 177-182 (1987) 4. Wertheim...
BioCentury | Sep 3, 2009
Distillery Therapeutics

Indication: Cancer

...Multiple issued patents; available for licensing from the University of Pennsylvania Center for Technology Transfer Wertheim...
BioCentury | Nov 24, 2008
Finance

Ebb & Flow

A deal with Eli Lilly (NYSE:LLY) for exclusive U.S. rights to commercialize tadalafil for pulmonary arterial hypertension last week couldn't prevent United Therapeutics (NASDAQ:UTHR) from getting hosed after its oral treprostinil missed the primary endpoint...
BioCentury | Aug 27, 2007
Company News

NeurAxon board of directors update

NeurAxon Inc. , Waltham, Mass. Business: Neurology Appointed: Deepa Pakianathan, general partner at Delphi Ventures; and Samuel Wertheimer, principal at OrbiMed Advisors LLC WIR Staff...
BioCentury | Aug 21, 2007
Financial News

NeurAxon raises $32 million

NeurAxon (Waltham, Mass.) raised $32 million in a series B round led by new investors Delphi Ventures and OrbiMed Advisors. Existing investors BDC Venture Capital; Genesys Capital; H.I.G. Ventures; NeuroVentures; Ventures West and new investor...
BioCentury | Jan 15, 2007
Company News

InteKrin board of directors update

InteKrin Therapeutics Inc. , Palo Alto, Calif. Business: Endocrine, Metabolic Appointed: Jim Healy, general partner at Sofinnova Ventures; Sam Wertheimer, principal at OrbiMed Advisors LLC; and Barry Selick, CEO of Threshold Pharmaceuticals Inc. WIR Staff...
BioCentury | Jan 12, 2007
Financial News

InteKrin raises $23 million

InteKrin (Palo Alto, Calif.) raised $23 million in a venture round led by new investor Sofinnova Ventures. OrbiMed Advisors and Vivo also joined existing investors Asset Management and Sears Capital Management in the round. InteKrin's...
BioCentury | Aug 7, 2006
Company News

Biodel board of directors update

Biodel Inc. , Danbury, Conn. Business: Drug delivery Appointed: David Kroin, cofounder and a managing director of Great Point Partners LLC; Albert Cha, a managing partner of Vivo Ventures; and Samuel Wertheimer, a principal of OrbiMed...
Items per page:
1 - 10 of 35
BioCentury | Mar 31, 2017
Targets & Mechanisms

Cells on the rise

...studies identified DCUND1 inhibitors that could help treat squamous cell carcinoma of the lung. Herbert Wertheim...
BioCentury | Aug 1, 2013
Tools & Techniques

The liver's new bud

...587-590 (1975) 3. Booth, C. et al. World J. Gastroenterol. 18 , 6926-6934 (2012) 4. Wertheim...
BioCentury | Mar 10, 2011
Targets & Mechanisms

De-amping the HER2 environment

...Boston, Mass. e-mail: jbaselga@partners.org 3. Slamon, D.J. et al. Science 235 , 177-182 (1987) 4. Wertheim...
BioCentury | Sep 3, 2009
Distillery Therapeutics

Indication: Cancer

...Multiple issued patents; available for licensing from the University of Pennsylvania Center for Technology Transfer Wertheim...
BioCentury | Nov 24, 2008
Finance

Ebb & Flow

A deal with Eli Lilly (NYSE:LLY) for exclusive U.S. rights to commercialize tadalafil for pulmonary arterial hypertension last week couldn't prevent United Therapeutics (NASDAQ:UTHR) from getting hosed after its oral treprostinil missed the primary endpoint...
BioCentury | Aug 27, 2007
Company News

NeurAxon board of directors update

NeurAxon Inc. , Waltham, Mass. Business: Neurology Appointed: Deepa Pakianathan, general partner at Delphi Ventures; and Samuel Wertheimer, principal at OrbiMed Advisors LLC WIR Staff...
BioCentury | Aug 21, 2007
Financial News

NeurAxon raises $32 million

NeurAxon (Waltham, Mass.) raised $32 million in a series B round led by new investors Delphi Ventures and OrbiMed Advisors. Existing investors BDC Venture Capital; Genesys Capital; H.I.G. Ventures; NeuroVentures; Ventures West and new investor...
BioCentury | Jan 15, 2007
Company News

InteKrin board of directors update

InteKrin Therapeutics Inc. , Palo Alto, Calif. Business: Endocrine, Metabolic Appointed: Jim Healy, general partner at Sofinnova Ventures; Sam Wertheimer, principal at OrbiMed Advisors LLC; and Barry Selick, CEO of Threshold Pharmaceuticals Inc. WIR Staff...
BioCentury | Jan 12, 2007
Financial News

InteKrin raises $23 million

InteKrin (Palo Alto, Calif.) raised $23 million in a venture round led by new investor Sofinnova Ventures. OrbiMed Advisors and Vivo also joined existing investors Asset Management and Sears Capital Management in the round. InteKrin's...
BioCentury | Aug 7, 2006
Company News

Biodel board of directors update

Biodel Inc. , Danbury, Conn. Business: Drug delivery Appointed: David Kroin, cofounder and a managing director of Great Point Partners LLC; Albert Cha, a managing partner of Vivo Ventures; and Samuel Wertheimer, a principal of OrbiMed...
Items per page:
1 - 10 of 35